Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Most pathogens initiate their infections at the human mucosal surface. Therefore, mucosal vaccination, especially through oral or intranasal administration routes, is highly desired for infectious diseases. Meanwhile, protein-based antigens provide a safer alternative to the whole pathogen or DNA based ones in vaccine development. However, the unique biopharmaceutical hurdles that intranasally or orally delivered protein vaccines need to overcome before they reach the sites of targeting, the relatively low immunogenicity, as well as the low stability of the protein antigens, require thoughtful and fine-tuned mucosal vaccine formulations, including the selection of immunostimulants, the identification of the suitable vaccine delivery system, and the determination of the exact composition and manufacturing conditions. This review aims to provide an up-to-date survey of the protein antigen-based vaccine formulation development, including the usage of immunostimulants and the optimization of vaccine delivery systems for intranasal and oral administrations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., Greenough, T. C., et al. (2003) · Nature · doi:10.1038/nature02145 · Cited by 5,923 · cited 2×
“…receptor binding domain of the spike protein of SARS-CoV/MERS-CoV is a promising antigen candidate since it binds to the human host-cell receptor, angiotensin-converting enzyme 2/dipep- tidyl peptidase 4 (Li et al., 2003; Wong et al., 2004; Graham et al., 2013; Lu et al., 2013; Zhang et al., 2014).”
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
CpG motifs in bacterial DNA trigger direct B-cell activation
Krieg, A. M., Yi, A.-K., Matson, S., Waldschmidt, T. J., Bishop, G. A., Teasdale, R., Koretzky, G. A., & Klinman, D. M. (1995) · Nature · doi:10.1038/374546a0 · Cited by 3,508
Fcγ receptors as regulators of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947 · cited 1×
“Protein Ag fused to IgG or Fc can specifically target IgG/ Fc-receptors constitutively expressed on APCs to enhance humoral and cellular immunity (Nimmerjahn and Ravetch, 2008; Gosselin et al., 2009) .”
STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity
Ishikawa, H., Ma, Z., & Barber, G. N. (2009) · Nature · doi:10.1038/nature08476 · Cited by 2,759 · cited 1×
“They are reported to interact with the transmembrane protein stimulator of interferon genes (STING), which then increases the production of type I interferons and further drives the adaptive immune response (Ishikawa et al., 2009; Burdette et al., 2011; Shaw et al., 2013).”
CD1d-Restricted and TCR-Mediated Activation of V α 14 NKT Cells by Glycosylceramides
Kawano, T., Cui, J., Koezuka, Y., Toura, I., Kaneko, Y., Motoki, K., Ueno, H., Nakagawa, R., Sato, H., Kondo, E., et al. (1997) · Science · doi:10.1126/science.278.5343.1626 · Cited by 2,400 · cited 3×
“It can be presented by APCs to potently activate natural killer T (NKT) cells, and modulate T cell immunity through efficient activation/maturation of DCs (Kawano et al., 1997).”
STING is a direct innate immune sensor of cyclic di-GMP
Burdette, D. L., Monroe, K. M., Sotelo-Troha, K., Iwig, J. S., Eckert, B., Hyodo, M., Hayakawa, Y., & Vance, R. E. (2011) · Nature · doi:10.1038/nature10429 · Cited by 1,570
Tam, J. P. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.15.5409 · Cited by 1,251 · cited 1×
“Tam developed the multiple antigenic peptide (MAP) system using a non-immunogenic lysine-based dendritic scaffold to improve the immunogenicity of subunit peptide vaccines (Tam, 1988).”
Towards an understanding of the adjuvant action of aluminium
Marrack, P., McKee, A. S., & Munks, M. W. (2009) · Nature Reviews Immunology · doi:10.1038/nri2510 · Cited by 887 · cited 1×
“Moreover, it is hindered for potential use in vaccine development of intracellular pathogens and tumors due to its incapability in inducing potent Th1 and CTL responses (Marrack et al., 2009; Reed et al., 2009).”
Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists
Kanzler, H., Barrat, F. J., Hessel, E. M., & Coffman, R. L. (2007) · Nature Medicine · doi:10.1038/nm1589 · Cited by 869 · cited 6×
“MPLA is the first TLR ligand (TLR4) approved for human vaccine, as a component of AS04 in the vaccine formulation against HPV and HBV (Kanzler et al., 2007; Mata-Haro et al., 2007).”
Influential
Cited by
Material design for lymph node drug delivery
Schudel, A., Francis, D. M., & Thomas, S. N. (2019) · Nature Reviews Materials · doi:10.1038/s41578-019-0110-7 · Cited by 460
Current state and challenges in developing oral vaccines
Vela Ramirez, J. E., Sharpe, L. A., & Peppas, N. A. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.04.008 · Cited by 412
Oral delivery of macromolecular drugs: Where we are after almost 100 years of attempts
Moroz, E., Matoori, S., & Leroux, J.-C. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.01.010 · Cited by 336
Platforms for Production of Protein-Based Vaccines: From Classical to Next-Generation Strategies
Cid, R., & Bolívar, J. (2021) · Biomolecules · doi:10.3390/biom11081072 · Cited by 176
Carbohydrate Immune Adjuvants in Subunit Vaccines
Bashiri, S., Koirala, P., Toth, I., & Skwarczynski, M. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12100965 · Cited by 45
“The immune-stimulatory capacity of α-GalCer was tested in combination with HIV CTL epitopes derived from gp120 envelope protein [54].”
BackgroundMethod
Metadata
- Authors
- Wang, S., Liu, H., Zhang, X., & Qian, F.
- Venue
- Protein & Cell
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-05-06
- Volume
- 6
- Issue
- 7
- Pages
- 480-503
- ISSN
- 1674-800X (ISSN-L)
- 1674-8018
- OpenAlex
- W2138541522
- Cited by
- 151
- References
- 15
- FWCI
- 3.87
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies. https://app.cochat.ai/papers/10.1007/s13238-015-0164-2
- The paper
- Wang, S., Liu, H., Zhang, X., & Qian, F. (2015). Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies. Protein & Cell. https://doi.org/10.1007/s13238-015-0164-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.